Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03558087 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
A Phase 2 study, sponsored by Matthew Galsky.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT03558087: Completed Phase 2 study, sponsored by Matthew Galsky.
NCT03558087 is a Phase 2 study that has completed, run by Matthew Galsky. The registered enrollment target is 76 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03558087, a Phase 2 study, has completed, sponsored by Matthew Galsky.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a phase 2 trial seeking to define the safety and activity of gemcitabine, cisplatin, plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to define the role of clinical complete response in predicting benefit in patients opting to avoid cystectomy.
Primary Outcome
Clinical complete response rate will be defined as the percentage of patients who achieved cT0 or cTa disease after gemcitabine, cisplatin, plus nivolumab.
Interventions
- DRUG Cisplatin
- DRUG Nivolumab
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2018-07-13 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 2 |
What the finished NCT03558087 record still lists
NCT03558087 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT03558087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03558087 about?
NCT03558087 is a clinical study titled "Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing". This is a phase 2 trial seeking to define the safety and activity of gemcitabine, cisplatin, plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to define the role of clinical complete response in predicting benefit in patients opting to avoid cystectomy.
What is the current status of trial NCT03558087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2018-07-13. Estimated completion is 2024-03-07.
What interventions are being tested in trial NCT03558087?
The interventions under investigation include: Cisplatin (DRUG), Nivolumab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT03558087?
This trial is sponsored by Matthew Galsky, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03558087's enrollment target sits among peer trials
76 893rd of 2000 higher than 1,101 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI